Načítá se...
Active surveillance in patients with a PSA >10 ng/mL
INTRODUCTION: The use of prostate-specific antigen (PSA) in active surveillance (AS) for prostate cancer is controversial. Some consider it an unreliable marker and others as sufficient evidence to exclude patients from AS. We analyzed our cohort of AS patients with a PSA over 10 ng/mL. METHODS: We...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Canadian Medical Association
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4216302/ https://ncbi.nlm.nih.gov/pubmed/25408810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2121 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|